Biopol Chemicals Limited
BIOO.NS is a specialty chemicals company that produces and sells chemical products, primarily generating revenue through the sale of these products to industrial and commercial customers.
Business. BIOO.NS is an Indian specialty chemicals company listed on the National Stock Exchange of India. The firm operates within the broader chemicals industry, focusing on the production and sale of chemical products. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the specialty chemicals sector.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BIOO.NS is an Indian specialty chemicals company listed on the National Stock Exchange of India. The firm operates within the broader chemicals industry, focusing on the production and sale of chemical products. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the specialty chemicals sector.
BIOO.NS has a debt-to-equity ratio of 0.57, indicating a moderate level of leverage, and a current ratio of 1.81, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company reported negative operating cash flow of -23,367,000 INR, which raises concerns about its ability to fund operations from core business activities. The free cash flow of 43,899,000 INR is positive, but the negative net cash position after subtracting total debt indicates potential liquidity constraints.
In terms of profitability, BIOO.NS has a return on equity (ROE) of 32.07% and a return on assets (ROA) of 13.8%, both of which are strong indicators of efficient use of equity and assets. These figures suggest the company is generating substantial returns relative to its equity and asset base. The operating income of 64,629,000 INR and net income of 43,434,000 INR further support the company's profitability.
The company's revenue is concentrated in a single business segment, as no specific segments are disclosed in the available data. There is no detailed geographic breakdown of revenue, but the company operates primarily in India, as indicated by the use of INR as the reporting currency. This lack of diversification may expose the company to regional economic and regulatory risks.
The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The capital expenditure of -245,000 INR suggests minimal investment in new assets, which may limit future growth potential. The absence of detailed outlook data makes it difficult to assess the company's future performance with certainty.
The risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The key flag of negative net cash after subtracting total debt highlights a potential liquidity issue. The company has not disclosed any dilutive events in the near term, and the dilution risk is assessed as low. The company's financial structure and the absence of significant dilutive events suggest a relatively stable capital structure.
There are no recent events or filings mentioned in the available data that would significantly impact the company's operations or financial position. The lack of recent disclosures or transcripts means that there is no additional information to consider regarding the company's strategic direction or operational performance.
- BIOO.NS has a strong return on equity (32.07%) and return on assets (13.8%), indicating efficient use of equity and assets.
- The company has a moderate debt-to-equity ratio of 0.57 and a current ratio of 1.81, suggesting a balanced capital structure.
- The negative operating cash flow of -23,367,000 INR raises concerns about the company's ability to fund operations from core business activities.
- The company's revenue is concentrated in a single business segment, with no detailed geographic breakdown provided.
- The company has a low dilution risk and no significant dilutive events disclosed in the near term.
- The lack of recent events or filings means there is no additional information to consider regarding the company's strategic direction or operational performance.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- BIOO.NS Market data — financials · 2026-05-27